IU researchers developing virtual-reality tool to treat substance abuse
The high-tech approach allows a patient recovering from substance abuse to interact with potential future versions of himself or herself.
R&D
Articles
Inotiv facing shareholder lawsuit over stock drop
The West Lafayette-based pharmaceutical testing company has seen its stock price soar—and later plunge—following its announcement last fall that it planned to acquire Indianapolis-based Envigo RMS LLC, which breeds and sells animals used in lab testing.
Fishers firm to help push injectables to market faster
A startup that’s planning to launch a $60 million drug-manufacturing plant sees big growth in contract manufacturing.
After years of turmoil, biotech testing firm aims to grow again
West Lafayette-based Bioanalytical Systems’ latest executive departure comes amid recent signs of stability, turnaround and growth for a company that just three years ago was on the verge of sinking.
Public-private partnership launching venue to test, develop 5G technologies
Indiana is positioning itself to be the epicenter for the latest generation of wireless technology, which experts say will be revolutionary.
Lilly’s push into pain research starting to pay off
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
Lilly bets billions on focus on cancer drugs
Long a leader in diabetes and neuroscience drugs, Eli Lilly and Co. is pushing hard and spending record sums to turbocharge its oncology business, potentially a huge growth area.
Indy startup Outpost Medicine draws in big money to develop drug therapies
For a startup that has raised an eye-popping $71 million in just three years, Outpost Medicine LLC likes to keep a low profile. The young company, which is developing drugs for urinary and gastrointestinal disorders, is headquartered in small, unmarked space at the Parkwood Crossing office complex on East 96th Street. It has issued only a […]
Opioid alternative from Lilly, Pfizer shows promise in study
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
Lilly might market diabetes drug for obesity after research results
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Competitor beats Lilly to market with migraine drug approval
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
China cuts red tape, increases potential for breakthrough medicines
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
New Lilly R&D chief planning blitz of drug launches
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
Another experimental Alzheimer’s drug fails as Eli Lilly, Astra halt tests
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.
Gene therapies that could transform diseases get easier FDA path
New therapies that could cure diseases caused by defective genes will get quicker approval from U.S. regulators, part of an effort by the Food and Drug Administration to keep pace with one of biotechnology’s fastest-growing fields.
Indiana life sciences firms raise record $111M in venture capital in 2017
A $44 million VC infusion in 2017 for biosciences firm On Target Laboratories was one indication that Indiana’s life sciences sector is finally starting to pull down some serious venture funding.
Lilly looks to boost pipeline with drug partnerships
A slimmed-down Eli Lilly and Co., thousands of employees lighter after its biggest restructuring in nearly a decade, is now looking high and low for deals to bulk up its drug pipeline.
Pfizer to end Alzheimer’s research, cut 300 jobs
Pfizer said it will continue its support of potential blockbuster drug tanezumab, a late-stage pain treatment in development with Indianapolis-based Eli Lilly and Co.
Assembly Biosciences’ market value surges to nearly $1B, despite red ink
The 5-year-old Carmel biotech has won plenty of attention from Wall Street and has secured more than $100 million through licensing deals and a stock offering to help fund expensive clinical trials.
Is marijuana debate at a tipping point?
A fight over whether Indiana should legalize medical marijuana seems all but inevitable now.